BioNTech halts colorectal cancer vaccine trial after safety review finds treatment unlikely to extend survival

BioNTech SE announced on August 28, 2026, that it will terminate its mid-stage trial of the experimental mRNA colorectal cancer vaccine autogene cevumeran, developed with Roche's Genentech. The decision follows an independent committee's finding of a 'numerical imbalance' in overall survival, suggesting more deaths in the vaccine group. This setback, which sent BioNTech's shares down 7.5%, highlights the difficulty of treating 'cold' tumors and shifts focus to its non-mRNA pipeline.

BioNTech trial termination

• ▪BioNTech SE is partnering with Roche's Genentech to develop the mRNA-based cancer vaccine autogene cevumeran
• ▪The terminated Phase II trial evaluated whether autogene cevumeran alone, administered after surgery and three months of chemotherapy, could prevent recurrence in high-risk, mid-stage colorectal cancer patients compared to standard watchful waiting
• ▪BioNTech SE announced on August 28, 2026, that it will end a mid-stage study of its experimental mRNA cancer vaccine, autogene cevumeran, for colorectal cancer

Survival imbalance safety findings

• ▪An independent committee overseeing the BioNTech SE trial of autogene cevumeran identified a 'numerical imbalance' in overall survival between patient groups, making it unlikely that continuing the trial would show the vaccine was effective
• ▪BMO Capital Markets analyst Evan Seigerman stated that the 'numerical imbalance' in overall survival in the BioNTech SE trial of autogene cevumeran is more concerning than a conventional futility stop, although the magnitude remains unclear
• ▪Analysts noted that the 'numerical imbalance' in the BioNTech SE trial of autogene cevumeran likely indicated that more deaths occurred in the vaccine group than in the control group

Merck-Moderna melanoma vaccine success

• ▪In August 2026, Merck and Moderna reported that their mRNA-based vaccine helped prevent the return and spread of melanoma in a trial of over 1,000 patients
• ▪The success of the Merck and Moderna melanoma vaccine trial had previously lifted BioNTech SE's shares by 20% on the day of the announcement

Cold tumor immunotherapy resistance

• ▪The failure of the colorectal cancer trial could dim prospects for BioNTech SE's remaining pancreatic cancer trial of autogene cevumeran, which is evaluating a combination therapy with Roche's Tecentriq and has data expected in 2031
• ▪Analysts stated that the BioNTech SE trial failure is a negative signal for mRNA vaccines in 'cold' tumors like colorectal and pancreatic cancers, which are historically resistant to immunotherapy

BioNTech strategic pipeline shift

• ▪The trial setback is expected to accelerate BioNTech SE's strategic shift toward its non-mRNA pipeline, including antibody-drug conjugates and bispecific cancer therapies like the experimental drug pumitamig
• ▪BioNTech SE is continuing development of other mRNA-based cancer therapies, including BNT113 for head and neck cancer, with interim data expected later in 2026

2 sources